Feasibility of Circulating Tumor DNA Analysis in Patients with Follicular Lymphoma.

ABSTRACT:

Purpose

The feasibility of sequencing circulating tumor DNA (ctDNA) in plasma as a biomarker to predict early relapse or poor prognosis in patients with follicular lymphoma (FL) receiving systemic immunochemotherapy is not clear.

Materials and methods

We sequenced DNA from cell-free plasma that was serially obtained from newly diagnosed FL patients undergoing systemic immunochemotherapy. The mutation profiles of ctDNA at the time of diagnosis and at response evaluation and relapse and/or progression were compared with clinical course and treatment outcomes.

Results

Forty samples from patients receiving rituximab-containing immunochemotherapy were analyzed. Baseline sequencing detected mutations in all cases, with the major detected mutations being KMT2C (50%), CREBBP

SUBMITTER: Yoon SE 

PROVIDER: S-EPMC11261198 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature